Adoptive Cellular Immunotherapy Market Report: Trends, Forecast and Competitive Analysis to 2031
상품코드:1859227
리서치사:Lucintel
발행일:2025년 11월
페이지 정보:영문 150 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계 입양 세포 면역요법 시장의 미래는 병원, 암 연구소 및 기타 시장에서의 기회로 인해 유망합니다. 입양 세포 면역요법 세계 시장은 2025년부터 2031년까지 23.1%의 연평균 성장률을 보일 것으로 예상됩니다. 이 시장의 주요 촉진요인은 암 발병률의 증가로 인해 입양 세포 면역요법에 대한 수요가 증가하고 있으며, 세포 치료의 발전으로 치료 효과와 치료 성적이 향상되고 있으며, 입양 세포 면역요법의 비용이 높다는 점입니다.
Lucintel의 예측에 따르면, 종류별로는 CAR-T 세포 치료제가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.
최종 용도별로는 병원이 가장 높은 성장이 예상됩니다.
지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장을 보일 것으로 예상됩니다.
입양 세포 면역요법 시장의 새로운 동향
입양 세포 면역요법 시장은 몇 가지 새로운 트렌드를 목격하고 있습니다. 이러한 추세는 세포 치료의 가능성 확대, 환자 예후 개선, 치료 범위 확대 등을 반영하고 있습니다.
고형암으로의 확대 : CAR-T 치료는 혈액암에서 큰 성공을 거두었지만, 고형암으로의 확대 사용에 대한 관심도 높아지고 있습니다. CAR-T 세포의 표적 메커니즘과 변형의 발전으로 CAR-T 세포는 유방암, 폐암, 난소암 등의 치료에 효과적임이 입증되고 있습니다. 이러한 확대는 입양 세포 치료의 영향력을 확대하는 중요한 추세입니다.
맞춤의료와 정밀의료 : 입양세포 치료는 환자 개개인의 유전자 프로파일에 맞는 치료를 하는 맞춤의료의 중요한 부분으로 자리 잡고 있습니다. 환자 맞춤형 CAR-T 세포 개발 등 치료의 맞춤화를 통해 보다 효과적인 치료와 예후 개선이 가능합니다. 이러한 추세는 환자들에게 고도로 표적화된 맞춤형 옵션을 제공함으로써 암 치료에 혁명을 불러일으키고 있습니다.
병용요법 : 입양세포면역치료와 면역관문억제제, 화학요법, 표적 치료제 등 다른 치료법과의 병용요법에 대한 관심이 높아지고 있습니다. 이 전략은 면역 반응을 강화하고, 내성 메커니즘을 극복하고, 전반적인 치료 효과를 향상시키는 것을 목표로 합니다. 병용요법은 다양한 암에 대한 조혈모세포 면역치료의 성공률을 높이는 중요한 원동력이 될 것으로 기대되고 있습니다.
규제 발전 및 승인 : 미국, 중국, 일본 등 주요 시장의 규제기관은 입양 세포 면역요법, 특히 CAR-T 치료제의 승인을 가속화하고 있습니다. 승인 절차의 간소화를 통해 치료제가 시장에 출시되기까지 걸리는 시간을 단축하고, 환자들에게 더 빠르게 접근할 수 있도록 돕고 있습니다. 이러한 추세는 CAR-T 치료제의 보급을 가속화하고 시장 성장을 촉진하는 데 매우 중요합니다.
비용 절감과 접근성 : 입양 세포 면역요법의 높은 가격은 큰 문제였습니다. 그러나 제조비용을 줄이고 확장성을 높이며 보다 저렴한 치료법을 개발하기 위한 노력이 활발히 진행되고 있습니다. 제조비용이 낮아지면, 특히 인도나 중국과 같은 개발도상국에서 더 많은 환자들이 이러한 첨단 치료법을 이용할 수 있게 될 것입니다.
고형암으로의 확대, 맞춤의료, 병용요법, 규제 상황의 발전, 비용 절감 등 입양 세포 면역요법 시장의 새로운 트렌드는 암 치료의 전망을 재구성하고 있습니다. 이러한 추세는 입양세포 치료가 전 세계 암 환자들에게 보다 효과적이고, 접근이 용이하며, 표적화된 치료 옵션을 제공할 수 있는 가능성을 높이고 있습니다.
입양 세포 면역요법 시장의 최근 동향
입양 세포 면역요법 시장은 기술 혁신, 새로운 임상시험 결과, 규제 당국의 승인으로 큰 진전을 보이고 있습니다. 이러한 발전으로 입양세포 치료의 범위가 확대되고, 다양한 암의 치료 효과가 향상되고 있습니다.
FDA 승인 CAR-T 치료제 : 미국에서는 Kymriah, Yescarta 등의 CAR-T 치료제가 백혈병, 림프종 등 혈액암 치료제로 승인되었습니다. 이번 승인으로 고형암으로 확대될 수 있는 길이 열렸습니다. 이러한 치료법의 성공은 CAR-T 세포의 채택을 촉진하여 면역치료 시장에서 중요한 발전이 되고 있습니다.
CAR-T 세포 제조의 기술적 진보 : CAR-T 세포 제조의 기술 혁신은 제조의 확장성, 비용 효율성, 속도를 향상시키고 있습니다. 새로운 자동화 기술은 생산 비용 절감에 도움을 주며, 입양 세포 면역 치료의 주요 과제 중 하나를 해결하고 있습니다. 생산 효율성이 높아지면 CAR-T 치료제의 가용성이 높아져 전 세계 더 많은 환자들이 치료제를 이용할 수 있게 될 것입니다.
임상시험 확대 : 미국, 중국, 인도 등 다양한 국가에서 입양 세포 면역치료제 임상시험이 빠르게 확대되고 있습니다. 이러한 임상시험은 새로운 적응증과 치료법 조합을 검토하고 있으며, 연구자들은 보다 광범위한 암에 대한 CAR-T 및 TIL 요법의 효능을 평가할 수 있게 되었습니다. 시험 건수의 증가는 시장 성장과 기술 혁신을 촉진하는 중요한 요소입니다.
신흥 시장에서의 규제 당국의 승인 : 중국, 일본과 같은 국가에서는 입양 세포 치료에 대한 규제 당국의 승인 절차가 간소화되어 해당 지역의 시장 성장을 가속화하고 있습니다. 규제 당국은 생명공학 기업들과 긴밀히 협력하여 혁신적인 치료법의 신속한 도입을 보장함으로써 CAR-T 치료에 대한 접근성을 개선하고 시장을 확대하기 위해 노력하고 있습니다.
생명공학기업과 제약기업의 전략적 제휴 : 생명공학기업과 대형 제약기업의 제휴는 입양 세포 면역치료제의 개발 및 상용화를 가속화하는 데 도움이 되고 있습니다. 이러한 협력은 CAR-T 및 기타 세포 치료제의 임상개발에 있어 매우 중요한 자원, 연구 및 전문지식의 공유를 가능하게 합니다. 이러한 제휴는 시장 확대에 중요한 역할을 하고 있습니다.
FDA 승인, 기술 혁신, 임상시험 확대, 규제 당국의 승인, 전략적 제휴 등 입양 세포 면역요법 시장의 최근 동향은 시장 성장을 촉진하고 있습니다. 이러한 발전으로 더 많은 환자들에게 입양세포 치료가 제공되어 암 치료의 판도를 바꿀 수 있는 잠재력을 가지고 있습니다.
목차
제1장 주요 요약
제2장 시장 개요
배경과 분류
공급망
제3장 시장 동향과 예측 분석
업계 성장 촉진요인과 과제
PESTLE 분석
특허 분석
규제 환경
제4장 세계의 입양 세포 면역요법 시장 : 종류별
개요
매력 분석 : 종류별
CAR-T 세포 치료 : 동향과 예측(2019-2031년)
NK 세포 치료 : 동향과 예측(2019-2031년)
TIL 요법 : 동향과 예측(2019-2031년)
기타 : 동향과 예측(2019-2031)
제5장 세계의 입양 세포 면역요법 시장 : 최종 용도별
개요
매력 분석 : 최종 용도별
병원 : 동향과 예측(2019-2031년)
암 연구소 : 동향과 예측(2019-2031년)
기타 : 동향과 예측(2019-2031)
제6장 지역 분석
개요
세계의 입양 세포 면역요법 시장 : 지역별
제7장 북미의 입양 세포 면역요법 시장
개요
북미의 입양 세포 면역요법 시장 : 종류별
북미의 입양 세포 면역요법 시장 : 최종 용도별
미국의 입양 세포 면역요법 시장
멕시코의 입양 세포 면역요법 시장
캐나다의 입양 세포 면역요법 시장
제8장 유럽의 입양 세포 면역요법 시장
개요
유럽의 입양 세포 면역요법 시장 : 종류별
유럽의 입양 세포 면역요법 시장 : 최종 용도별
독일의 입양 세포 면역요법 시장
프랑스의 입양 세포 면역요법 시장
스페인의 입양 세포 면역요법 시장
이탈리아의 입양 세포 면역요법 시장
영국의 입양 세포 면역요법 시장
제9장 아시아태평양의 입양 세포 면역요법 시장
개요
아시아태평양의 입양 세포 면역요법 시장 : 종류별
아시아태평양의 입양 세포 면역요법 시장 : 최종 용도별
일본의 입양 세포 면역요법 시장
인도의 입양 세포 면역요법 시장
중국의 입양 세포 면역요법 시장
한국의 입양 세포 면역요법 시장
인도네시아의 입양 세포 면역요법 시장
제10장 기타 지역(ROW)의 입양 세포 면역요법 시장
개요
ROW의 입양 세포 면역요법 시장 : 종류별
ROW의 입양 세포 면역요법 시장 : 최종 용도별
중동의 입양 세포 면역요법 시장
남미의 입양 세포 면역요법 시장
아프리카의 입양 세포 면역요법 시장
제11장 경쟁 분석
제품 포트폴리오 분석
운영 통합
Porter's Five Forces 분석
경쟁 기업 간의 경쟁 관계
구매자의 협상력
공급업체의 협상력
대체품의 위협
신규 참여업체의 위협
시장 점유율 분석
제12장 기회와 전략 분석
밸류체인 분석
성장 기회 분석
성장 기회 : 종류별
성장 기회 : 최종 용도별
세계의 입양 세포 면역요법 시장 최신 동향
전략 분석
신제품 개발
인증·라이선싱
기업 인수합병(M&A) , 계약, 제휴, 합작투자
제13장 밸류체인 전반에 걸친 주요 기업 개요
경쟁 분석
Bristol-Myers Squibb Company
Novartis AG
Gilead Sciences Inc.
F. Hoffmann-La Roche Ltd
Merck KGaA
제14장 부록
그림목차
표목차
분석 방법
면책사항
저작권
약어와 기술 단위
Lucintel 소개
문의
KSM
영문 목차
영문목차
The future of the global adoptive cellular immunotherapy market looks promising with opportunities in the hospitals, cancer institutes, and others markets. The global adoptive cellular immunotherapy market is expected to grow with a CAGR of 23.1% from 2025 to 2031. The major drivers for this market are the growing cancer incidence drives demand for adoptive cellular immunotherapies., the advancements in car-t cell therapies enhance treatment efficacy and outcomes., and the high cost of adoptive cellular immunotherapies.
Lucintel forecasts that, within the type category, car t cell therapy is expected to witness the highest growth over the forecast period.
Within the application category, hospitals is expected to witness the highest growth.
In terms of region, APAC is expected to witness the highest growth over the forecast period.
Emerging Trends in the Adoptive Cellular Immunotherapy Market
The market for adoptive cellular immunotherapy is witnessing several emerging trends that are reshaping the landscape. These trends reflect the growing potential of cellular therapies, improving patient outcomes, and expanding the scope of treatment.
Expansion to Solid Tumors: While CAR-T therapies have shown significant success in hematologic cancers, there is increasing focus on expanding their use to solid tumors. Advances in targeting mechanisms and modifications to CAR-T cells are making them more effective in treating cancers such as breast, lung, and ovarian cancers. This expansion represents a key trend in broadening the impact of adoptive cellular therapies.
Personalized and Precision Medicine: Adoptive cellular therapies are becoming an integral part of personalized medicine, where treatments are tailored to the individual genetic profiles of patients. The customization of therapies, including the development of patient-specific CAR-T cells, allows for more effective treatment and improved outcomes. This trend is revolutionizing cancer treatment by offering highly targeted, individualized options for patients.
Combination Therapies: There is growing interest in combining adoptive cellular immunotherapy with other treatment modalities, such as immune checkpoint inhibitors, chemotherapy, and targeted therapies. This strategy aims to enhance the immune response, overcome resistance mechanisms, and improve overall treatment efficacy. Combination therapies are expected to be a crucial driver in increasing the success rate of adoptive cellular immunotherapy for diverse cancers.
Regulatory Advancements and Approvals: Regulatory bodies in key markets like the U.S., China, and Japan are accelerating the approval of adoptive cellular immunotherapies, especially CAR-T therapies. Streamlined approval processes are reducing the time it takes for therapies to reach the market, facilitating quicker access for patients. This trend is crucial in accelerating the availability of these therapies ly and driving market growth.
Cost Reduction and Accessibility: The high cost of adoptive cellular immunotherapies has been a significant challenge. However, efforts to reduce manufacturing costs, improve scalability, and develop more affordable therapies are gaining momentum. As the cost of production decreases, accessibility will improve, making these advanced therapies available to a wider range of patients, particularly in developing countries like India and China.
The emerging trends in the adoptive cellular immunotherapy market, including the expansion to solid tumors, personalized medicine, combination therapies, regulatory advancements, and cost reduction, are reshaping the landscape of cancer treatment. These trends are enhancing the potential for adoptive cellular therapies to offer more effective, accessible, and targeted treatment options for cancer patients worldwide.
Recent Developments in the Adoptive Cellular Immunotherapy Market
The adoptive cellular immunotherapy market has seen significant advancements driven by technological innovations, new clinical trial results, and regulatory approvals. These developments are expanding the scope of adoptive cellular therapies and improving their effectiveness in treating various cancers.
FDA-Approved CAR-T Therapies: In the U.S., CAR-T therapies like Kymriah and Yescarta have been approved for the treatment of hematologic cancers such as leukemia and lymphoma. These approvals have paved the way for further expansion into solid tumors. The success of these therapies is driving the adoption of CAR-T cells, making them a key development in the immunotherapy market.
Technological Advancements in CAR-T Manufacturing: Innovations in CAR-T cell manufacturing are improving the scalability, cost-effectiveness, and speed of production. New automated technologies are helping reduce production costs, addressing one of the major challenges in adoptive cellular immunotherapy. As manufacturing becomes more efficient, the availability of CAR-T therapies will increase, making these treatments accessible to more patients worldwide.
Expansion of Clinical Trials: Clinical trials for adoptive cellular immunotherapies are rapidly expanding across various countries, including the U.S., China, and India. These trials are exploring new indications and combinations of therapies, allowing researchers to assess the efficacy of CAR-T and TIL therapies for a wider range of cancers. The increasing number of trials is a key factor driving market growth and innovation.
Regulatory Approvals in Emerging Markets: Countries like China and Japan are streamlining regulatory approval processes for adoptive cellular therapies, which is accelerating the market growth in these regions. Regulatory agencies are working closely with biotech companies to ensure the swift introduction of innovative therapies, improving access to CAR-T treatments and expanding the market ly.
Strategic Collaborations Between Biotech and Pharma: Collaborations between biotech firms and large pharmaceutical companies are helping accelerate the development and commercialization of adoptive cellular immunotherapies. These partnerships enable the sharing of resources, research, and expertise, which is crucial in advancing the clinical development of CAR-T and other cellular therapies. Such collaborations are playing a significant role in expanding the market.
Recent developments in the adoptive cellular immunotherapy market, including FDA approvals, technological innovations, expansion of clinical trials, regulatory approvals, and strategic collaborations, are driving the growth of the market. These advancements are bringing adoptive cellular therapies to more patients, with the potential to transform cancer treatment.
Strategic Growth Opportunities in the Adoptive Cellular Immunotherapy Market
The growing demand for adoptive cellular therapies presents significant strategic growth opportunities across various applications. These opportunities are expected to expand the market, enhance treatment options, and improve patient outcomes.
Expanding Indications for CAR-T Therapy: One of the major growth opportunities lies in expanding CAR-T therapies to treat solid tumors. Research is ongoing to adapt CAR-T cells to target cancers such as lung, breast, and pancreatic cancer. Success in this area could open up a vast new market for adoptive cellular immunotherapies, revolutionizing cancer treatment.
Combination of CAR-T with Other Immunotherapies: The combination of CAR-T therapies with other immunotherapies, such as checkpoint inhibitors or monoclonal antibodies, is a promising growth opportunity. This strategy can potentially enhance the immune response and improve overall treatment efficacy. By addressing treatment resistance and increasing tumor targeting, combination therapies could become a key development in the market.
Personalized Immunotherapy Approaches: Personalized medicine, including the use of patient-specific CAR-T therapies, presents significant growth potential. As advancements in genomics and cellular engineering continue, customized treatments tailored to individual patients' genetic profiles will become more prevalent, making adoptive cellular therapies more effective and offering better patient outcomes.
Regulatory Expediting in Emerging Markets: Emerging markets like China and India represent significant growth opportunities for adoptive cellular immunotherapy. As these countries streamline regulatory processes and expand access to innovative treatments, biotech companies can tap into large, underserved patient populations. This trend is expected to contribute significantly to market growth.
Manufacturing Cost Reduction: Reducing the cost of CAR-T and other cellular therapies is a critical growth opportunity. Innovations in manufacturing processes, such as automation and scale-up techniques, will drive down costs, making these therapies more affordable and accessible to a broader population. Lower costs will drive adoption and increase market size.
Strategic growth opportunities in the adoptive cellular immunotherapy market, including expanding indications, combination therapies, personalized medicine, regulatory progress in emerging markets, and manufacturing cost reduction, are poised to drive market expansion. These opportunities will help transform the landscape of cancer treatment, offering more accessible and effective options for patients ly.
Adoptive Cellular Immunotherapy Market Driver and Challenges
The adoptive cellular immunotherapy market is influenced by a range of technological, economic, and regulatory factors. These drivers and challenges impact the development, adoption, and scalability of adoptive cellular therapies. Understanding these elements is crucial for stakeholders seeking to navigate the complex landscape of adoptive immunotherapies, which show promising potential in treating cancer and other diseases but also face significant barriers.
The factors responsible for driving the Adoptive Cellular Immunotherapy Market include:
1. Advancements in Cell Therapy Technologies: Technological innovations in gene editing, stem cell research, and cell expansion techniques have led to more effective and scalable adoptive cellular therapies. These advancements enable higher success rates and improve patient outcomes, which drives growth in the market.
2. Increasing Cancer Incidence: The growing burden of cancer is a significant driver for adoptive cellular immunotherapies. As more patients seek advanced cancer treatments, the demand for immunotherapies like CAR-T and TIL therapies increases, expanding market opportunities.
3. Rising Investment and Funding in Immunotherapy: Increased investment from both public and private sectors into research, clinical trials, and production facilities is accelerating the development of adoptive cellular therapies. This influx of funding drives innovation and supports the commercialization of these therapies.
4. Shifting Focus Towards Personalized Medicine: There is a growing emphasis on personalized medicine, which tailors treatments to individual patients based on their genetic and molecular profiles. Adoptive cellular immunotherapies, such as CAR-T, are well-suited for this trend, further driving their market demand.
5. Regulatory Approvals and Market Expansion: The growing number of regulatory approvals for adoptive cellular immunotherapies, such as CAR-T, is opening new market avenues. These approvals make these therapies more accessible to patients and stimulate growth within the market.
Challenges in the Adoptive Cellular Immunotherapy Market are:
1. High Treatment Costs: The production of adoptive cellular therapies involves complex, personalized processes, leading to high treatment costs. These expenses can limit access to therapies, particularly in low-income regions, and hinder wider adoption, impacting overall market growth.
2. Manufacturing and Scalability Issues: The current manufacturing process for adoptive cellular therapies is labor-intensive, time-consuming, and difficult to scale. This limits the ability to meet growing patient demand and presents challenges to market expansion.
3. Safety and Efficacy Concerns: Despite positive results, the safety and efficacy of adoptive cellular therapies can vary. Adverse effects, such as cytokine release syndrome and neurotoxicity, as well as inconsistent outcomes, remain a challenge, which can undermine patient confidence and slow market adoption.
The adoptive cellular immunotherapy market is shaped by advancements in technology, growing cancer rates, and increasing funding for research. However, high treatment costs, manufacturing challenges, and concerns about safety and efficacy present significant obstacles. Balancing these drivers and challenges will be key to determining the market's future success and its potential for widespread adoption.
List of Adoptive Cellular Immunotherapy Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies adoptive cellular immunotherapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the adoptive cellular immunotherapy companies profiled in this report include-
Bristol-Myers Squibb Company
Novartis AG
Gilead Sciences Inc.
F. Hoffmann-La Roche Ltd
Merck KGaA
Adoptive Cellular Immunotherapy Market by Segment
The study includes a forecast for the global adoptive cellular immunotherapy market by type, end use, and region.
Adoptive Cellular Immunotherapy Market by Type [Value from 2019 to 2031]:
Car T Cell Therapy
Nk Cell Therapy
Til Therapy
Others
Adoptive Cellular Immunotherapy Market by End Use [Value from 2019 to 2031]:
Hospitals
Cancer Institutes
Others
Adoptive Cellular Immunotherapy Market by Region [Value from 2019 to 2031]:
North America
Europe
Asia Pacific
The Rest of the World
Country Wise Outlook for the Adoptive Cellular Immunotherapy Market
The market for adoptive cellular immunotherapy is experiencing rapid growth as this innovative approach continues to transform cancer treatment. By harnessing the power of the immune system, adoptive cellular therapies such as CAR-T and TIL therapies are gaining attention in the fight against various cancers. The United States, China, Germany, India, and Japan are leading advancements in research, clinical trials, and regulatory approvals, shaping the landscape for these therapies.
United States: The U.S. remains a leader in adoptive cellular immunotherapy, with CAR-T cell therapies such as Kymriah and Yescarta being FDA-approved for multiple cancers. Ongoing research focuses on overcoming challenges like treatment resistance and expanding applications beyond blood cancers to solid tumors. The high demand for personalized therapies and strong financial investment from biotech and pharmaceutical companies are driving the rapid development of these therapies.
China: China is making significant strides in adoptive cellular immunotherapy, especially in the development of CAR-T therapies. Chinese companies are leading in the commercialization of cost-effective therapies for blood cancers and have started conducting clinical trials for solid tumors. Regulatory authorities in China are accelerating approval processes, making the country an emerging market for CAR-T cell therapies, and they are looking to expand to more affordable options for patients.
Germany: Germany is at the forefront of adoptive cellular immunotherapy research in Europe. Strong collaborations between academic institutions and pharmaceutical companies have advanced CAR-T and TIL (Tumor-Infiltrating Lymphocyte) therapies, particularly for hematologic cancers. The country's supportive regulatory framework and focus on personalized medicine are accelerating the development of these therapies, with increasing participation in clinical trials and ongoing research to enhance efficacy and minimize side effects.
India: India's adoptive cellular immunotherapy market is gaining momentum, especially with an increase in clinical trials for CAR-T therapies. Research institutions and biotech companies are partnering with international firms to expand access to innovative therapies. With a large population of cancer patients, particularly those with blood cancers, India is becoming a significant player in the adoption of CAR-T therapies, though affordability and accessibility remain key challenges.
Japan: Japan has been advancing in adoptive cellular immunotherapy, with several clinical trials focused on CAR-T and TIL therapies. Japan's efficient healthcare system and regulatory processes are conducive to the approval and rapid adoption of these therapies. Additionally, collaborations with international biotech companies are facilitating the development of new treatments. Japan is particularly focused on expanding these therapies to treat a wider range of cancers, including solid tumors.
Features of the Global Adoptive Cellular Immunotherapy Market
Market Size Estimates: Adoptive cellular immunotherapy market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Adoptive cellular immunotherapy market size by type, end use, and region in terms of value ($B).
Regional Analysis: Adoptive cellular immunotherapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, end use, and regions for the adoptive cellular immunotherapy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the adoptive cellular immunotherapy market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the adoptive cellular immunotherapy market by type (car t cell therapy, nk cell therapy, til therapy, and others), end use (hospitals, cancer institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Table of Contents
1. Executive Summary
2. Market Overview
2.1 Background and Classifications
2.2 Supply Chain
3. Market Trends & Forecast Analysis
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment
4. Global Adoptive Cellular Immunotherapy Market by Type
4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 CAR T Cell Therapy: Trends and Forecast (2019-2031)
4.4 NK Cell Therapy: Trends and Forecast (2019-2031)
4.5 TIL Therapy: Trends and Forecast (2019-2031)
4.6 Others: Trends and Forecast (2019-2031)
5. Global Adoptive Cellular Immunotherapy Market by End Use
5.1 Overview
5.2 Attractiveness Analysis by End Use
5.3 Hospitals: Trends and Forecast (2019-2031)
5.4 Cancer Institutes: Trends and Forecast (2019-2031)
5.5 Others: Trends and Forecast (2019-2031)
6. Regional Analysis
6.1 Overview
6.2 Global Adoptive Cellular Immunotherapy Market by Region
7. North American Adoptive Cellular Immunotherapy Market
7.1 Overview
7.2 North American Adoptive Cellular Immunotherapy Market by type
7.3 North American Adoptive Cellular Immunotherapy Market by end use
7.4 United States Adoptive Cellular Immunotherapy Market
